These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20471823)

  • 1. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
    Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
    Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
    Saad F; Lipton A
    Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA; Lebwohl D
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
    Goss PE
    Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer.
    Hiscox S; Morgan L; Green T; Nicholson RI
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S53-9. PubMed ID: 17259559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
    Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer adjuvant endocrine therapy.
    Cigler T; Goss PE
    Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF; Davis J
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
    Johnston SR
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S145-57. PubMed ID: 16113091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.